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Alzheimer’s  disease  (AD),  the  most  common  age-associated  dementing  disorder,  is clin-
copathologically  manifested  by  progressive  cognitive  dysfunction  concomitant  with  the
accumulation  of senile  plaques  (SP).  SP  is  consisting  of amyloid-  (A)  peptides  and  neu-
roﬁbrillary  tangles  (NFTs)  of hyper-phosphorylated  tau  (p-tau)  protein  aggregates  in  the
brain of  affected  individuals.  Lipid  rafts promote  interaction  of the  amyloid  precursor  pro-
tein (APP)  with  the -secretase  enzyme  responsible  for generation  of  the A  peptides.
Fibrillar  A  oligomers,  which  have  been  shown  to  correlate  with  the  onset  and  severity  of
AD,  bind  preferentially  to cells  and neurons  expressing  cellular  prion  protein  (PrPC). The
binding  of  A  oligomers  to cell surface  PrPC, as well  as  their  downstream  activation  of
Fyn  kinase,  was dependent  on  the  integrity  of  cholesterol-rich  lipid  rafts.  Rafts  also  regu-
late cholinergic  signaling  as  well  as  acetylcholinesterase  and  A  interaction.  Such  major
lipid raft  components  as  cholesterol  and ganglioside  (GM1)  have  been  directly  implicated
in  pathogenesis  of  the  disease.  Perturbation  of lipid  raft  integrity  can  also  affect various
signaling  pathways  leading  to cellular  death  and  AD.
In this  review,  I will  discuss  the  more  recent  ﬁndings  on  the  biopathological  mechanisms,
candidate  bio-markers,  and  therapeutic  interventions  of the  elusive  AD.
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1. Introduction
Alzheimer’s disease (AD) is a common, progressive and
devastating neuro-degeneration of human brain structure
and  function, from which over 37 million people are suffer-
ing  worldwide [1] with an estimated cost of $600 billion in
2010  [2]. Globally, 5 million new cases of AD are diagnosed
annually, with one new AD case being reported every 7 s [3].
The  risk of developing AD correlates strongly with aging,
resulting in a deterioration of mood, behavior, functional
ability, cognition, and memory [4], therefore, AD is becom-
ing  an increasing socio-economic crisis as life expectancy
increases. Taking care of AD patients places a tremendous
socioeconomic burden not only on unpaid caregivers but
on  our health care system as a whole [5]. In spite of this,
there is no current therapy that can halt or reverse AD
[6].
The  disease is associated with brain pathology involv-
ing accumulation of extracellular amyloid aggregates (also
known  as senile plaques) (SP) of small, toxic, and highly
amyloidogenic 42 amino acid amyloid beta (A42) pep-
tides  and intracellular neuroﬁbrillary tangles (NFTs) of
hyper-phosphorylated tau (p-tau) protein [7,8]. Accord-
ing  to the amyloid cascade hypothesis, it is the A which
is  principally responsible for many of the pathological
features of the disease with A oligomers representing
the most toxic species [9]. The accumulation of A42 as
diffuse  plaques triggers the inﬂammatory responses due
to  microglial activation with release of pro-inﬂammatory
cytokines and the most affected brain areas are the neo-
cortex  and hippocampus. In addition, perturbations in the
equilibrium between kinases and phosphatases resulting
in  hyperphosphorylation of tau protein that results in neu-
ronal  degeneration and neuronal loss [10].
Allam et al. [11] strongly suggested through the results
of  their bioinformatics study that presenilins (PS-1, PS-2)
and  amyloid precursor protein (APP) play a dominant role
in  the pathogenesis of AD by inducing a pro-inﬂammatory
state; raises the possibility that genetic components
are more important in AD compared to environmental,
metabolic, and age related factors.. .  .  .  . . .  .  .  . . . . . .  .  . . . . . . .  . . . .  .  . .  . . .  .  . . . .  . . . . . . .  . .  . . . . . . . . .  . . . . .  . .  .  .  65
Although there are strong genetic links, including APP,
PS-1,  and PS-2 mutations [12], as well as the apolipopro-
tein 4 allele [13], sporadic AD is the dominant form. From
this  point of view pre-dominance of AD research based on
the  mechanisms of early onset disease versus the broader
spectrum of the factors leading to the sporadic form might
be  one of the reasons for the failure of the majority of ther-
apeutic trials and lack of any preventive measures 20 years
since  the amyloid hypothesis has been proposed [14].
In  this review, I will elaborate on the current status of
research addressing the biopathological mechanisms, can-
didate  bio-markers, and therapeutic interventions of the
elusive  AD.
2.  Lipid rafts
The  notion of lipid rafts, while not new, has never
been far from controversy, their existence frequently
questioned. They are small nanodomains (10–200 nm),
heterogeneous, highly dynamic of which there are millions
in  a single cell [15]. They have recently gained consid-
erable attention as these membrane-embedded clusters
of  phospholipid-sphingolipid- and cholesterol-enriched,
integral and peripheral membrane proteins are instru-
mental in the processing of APP holoprotein and hence
the  amyloidogenic process itself [16,17]. Small rafts can
sometimes be stabilized to form larger platforms through
protein–protein and protein–lipid interactions” [15]. The
long,  saturated acyl chains of sphingolipids allow tight
packing hence their juxtaposition with the kinked, unsat-
urated  acyl chains of bulk membrane phospholipids leads
to  phase separation. The cholesterol molecules can act as
“spacers,”  ﬁlling any gaps in sphingolipid packing [18].
Pike  [15] showed the importance of lipid rafts in protein
sorting and segregation with glycosylphosphatidylinositol
(GPI)-anchored proteins, being preferentially localized in
lipid  rafts. Other lipid modiﬁcations of proteins have also
been  described, such as palmitoylation and myristoylation
which may  inﬂuence raft localization [15]. In describing
membrane lipid clusters as moving platforms, or rafts per-
haps  the most important ﬁnding was that proteins could
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r  obstruct protein interactions or act as a protein scaffold
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. Lipid raft components and their changes in AD
.1.  Raft localization of APP and secretases
Interestingly, all of the enzymatic machinery respon-
ible for the generation of A42, and subsequent SP
ormation, are plasma membrane-resident secretases
ith modiﬁer/accelerator/accessory proteins that are
nvolved in the catabolic processing of the membrane-
ound beta-APP. Beside the -secretase; presenilins
re transmembrane proteins localized predominantly
n the endoplasmic reticulum (ER) and Golgi apparatus.
he accelerator proteins include nicastrin, aph-1, pen-2,
ortilin, TSPAN membrane proteins, and others [5] interact
ith  PS-1 and PS-2 to form a large enzymatic complex
nown as -secretase that cleaves APP to generate A [20].
n  addition, they interact with antiapoptotic Bcl-2 through
uman FK506-binding protein 38, thus it may  regulate the
poptotic  cell death [21].
.2.  Generation of Aˇ42
A  is cleaved out of the APP through the sequential
ction of the -secretase and the PS-containing -secretase
omplex “amyloidogenic pathway”. In the alternative,
non-amyloidogenic pathway”, APP is ﬁrst cleaved by the
-secretase, members of the ADAM (a disintegrin and
etalloprotease) family of zinc metalloproteases, within
he  A sequence thus precluding production of intact A
eptides [22].
.3.  Cellular mechanisms of A  ˇ oligomer-mediated
eurotoxicity
.3.1. Cellular prion protein (PrPC) signaling in AD
The key event driving AD pathogenesis is the accumu-
ation of the 40–43 residue A peptides in the brain [23].
he  peptides, particularly A1–42, are aggregation prone,
elf-assembling to form a heterogeneous mixture of soluble
ligomers, protoﬁbrils and ﬁbrils. Only levels of the soluble,
brillar  oligomers were found to be elevated signiﬁcantly
n AD brains, where their levels correlate strongly with
D  onset-severity, and are therefore proposed to be the
ajor  neurotoxic species in AD [24]. Consequent delete-
ious  effects include neurotoxicity, memory impairments,
nhibition of long-term potentiation (LTP), loss of den-
ritic  spines and synaptic dysfunction [25]. The cellular
echanisms of A oligomer-mediated neurotoxicity are,
owever, poorly deﬁned [26].
The cellular prion protein (PrPC) was identiﬁed as a
igh-afﬁnity receptor for A oligomers [27]. PrPC is a GPI
nchored cell surface glycoprotein. It is a neuroprotective
nd plays important roles in limitation of excessive N-
ethyl-d-aspartate (NMDA) receptor activity which might
ause  neuronal damage, neuronal oxidative stress defense,and Ultrastructure 2 (2014) 57–66 59
and  metal ion homeostasis in the brain [28]. It also lowered
A  production through the inhibition of -secretase [29].
However, ﬁbrillar A oligomers, but not monomers or
ﬁbrils,  bound tightly to PrPC [27,30] and the presence of
PrPC in hippocampal slices was  shown to be responsible for
the  ﬁbrillar A oligomer-mediated inhibition of LTP [27]
and  the manifestation of memory impairments in an AD
mouse  model [25]. Recent studies have identiﬁed PrPC as
a  critical modulator of the AD-related synaptic dysfunc-
tion and cognitive impairments caused by A oligomers
[31]. Rushworth et al. [26] revealed details of the molecular
and  cellular mechanisms underpinning the PrPC-ﬁbrillar
A  oligomer interaction and the resulting downstream cel-
lular  events.
Fibrillar A oligomers cointernalised with PrPC from the
cell  surface and then trafﬁcked to endosomes and lyso-
somes through low-density lipoprotein receptor-1 (LRP1)
which  is highly expressed in neuronal cells. It is a trans-
membrane protein that facilitates the clathrin-mediated
endocytosis of PrPC [32] and has also been implicated in
the  neuronal uptake of A oligomers [33]. Rushworth et al.
[26]  indicated that LRP1 functions as a transmembrane
co-receptor that is involved in the A oligomers-PrPC inter-
action  and is required for their internalization, and cytotox-
icity  of the A oligomers. Um et al. [34] revealed that PrPC
also mediates the transcytosis of monomeric A40 across
the  blood-brain barrier (BBB). The ability of ﬁbrillar A
oligomers to stimulate the endocytosis of PrPC, thus lower-
ing  its cell surface expression, impaired the ability of PrPC
to inhibit -secretase, hence increasing the amyloidogenic
processing of APP [26]. Thus, PrPC is no longer protective
but contributes to A oligomer neurotoxicity and further
A  production in a toxic, positive feedback loop. In addi-
tion,  PrPC was  required for the downstream cytotoxicity
of the ﬁbrillar A oligomers through the activation of a
member of the Src family kinases (SFK), Fyn kinase. The
latter  is implicated in multiple pathways that underlie AD
[35],  including mediating the toxicity of A oligomers and
linking  A to tau toxicity [36], NMDA receptor phospho-
rylation and cell surface distribution, dendritic spine loss
and  lactate dehydrogenase [34]. PrPc together with the
data  on -secretase regulation provides a unifying molec-
ular  mechanism explaining the interplay between toxic
A  species, NMDA receptor-mediated toxicity and copper
homeostasis in pathogenesis of AD [37]. Interestingly, the
interaction of PrPC with -secretase [29] and the interac-
tion of PrPC with LRP1 [32] are both dependent upon the
polybasic N-terminal sequence (KKRP) of PrPC. This same
region  is also the crucial determinant of PrPC-mediated A
oligomer  binding and toxicity. Surface plasmon resonance
studies showed that deletion of the N-terminus blocked
the  toxicity of natural A oligomers [38]. Thus, this region
appears to be critical to a number of functions of PrPC,
although its role in protective functions raises questions,
would be a viable approach for the treatment of AD?  [26].
Rushworth et al. [26] found that not only the bind-
ing of the oligomers to PrPC but also the downstream
signaling mechanisms is dependent on the integrity of the
raft  microdomains, disruption of the rafts caused a signif-
icant  (80%) reduction in A oligomer binding to the cells
and  prevented the activation of Fyn kinase.
roscopy 60 R.A.K.M. El-Desouki / Journal of Mic
The importance of using well-deﬁned oligomer con-
formations for biological activity potentially explain the
discrepancies in results showing a lack of PrPC-dependence
of A oligomer toxicity, as different studies have employed
distinct, often poorly characterized A oligomer prepara-
tions or unnatural APP constructs which may  not lead to the
generation  of biologically relevant A oligomers [23]. As
the  conformation of ﬁbrillar A oligomers is a critical deter-
minant  of their PrPC-mediated binding and subsequent
toxicity so, disrupting the conformation of A oligomers
could also be a potential therapeutic approach for AD [22].
Tau  is a microtubule-associated protein that stabilizes
neuronal microtubules under normal physiological condi-
tions,  however in AD, A induces tau phosphorylation that
can  result in the generation of aberrant aggregates that are
toxic  to neurons [39]. Mutations in tau give rise to NFTs but
not  plaques and mutations in APP or in the probable APP
proteases give rise to both plaques and tangles indicates
that amyloid pathology occurs upstream of tau pathology
[11].
A  accumulation can be affected by numerous factors
including increased rates of its production and/or impaired
clearance. There are numerous proteases in the brain that
participate in A degradation and clearance including
cathepsins, gelatinases, endopeptidases, aminopeptidase,
neprilysin, serine protease, and insulin-degrading enzyme
(IDE)  [40]. Genetic linkage studies have also linked AD and
plasma  A42 levels to chromosome 10q, which harbors the
IDE  gene. IDE has been observed in human cerebrospinal
ﬂuid (CSF); and its activity levels and m-RNA are decreased
in  AD brain tissue and is associated with increased A levels
[41].
3.4.  APP sorting, transport, trafﬁcking and processing
Although the function of APP remains to be fully eluci-
dated, understanding APP trafﬁcking and processing would
also  provide new insights into the regulatory mechanism
of  the amyloidogenic pathway. The processing of APP
involves numerous steps, including APP sorting, transport,
internalization and sequential proteolysis [42]. Newly
synthesized APP in ER is sorted through the trans-Golgi-
network (TGN), trafﬁcked to the cell surface membrane,
and internalized via its NPTY motif near the C terminus of
APP  into endosome/TGN for recycling or into lysosome for
degradation [43]. Altered routing of APP trafﬁcking and
distribution in neurons might lead to the amyloidogenic
pathway, which is implicated in the pathology of AD.
Hence, the intracellular distribution and transport of APP
are  critical for A production [44]. Sortilin is important
in neuronal functions and shares genetic similarity with
other  Vps10p family members, such as SorLA, SORCS1
and SORCS2 [45]. SorLA is down-regulated but sortilin is
up-regulated in AD [46]. SorLA is reported to retain APP
in  Golgi, this can lead to decreasing Ab production. Mean-
while,  sortilin is associated with APP via head-to-head (the
extracellular domain) and tail-to-tail (the intracellular
domain) interactions; it regulates APP lysosomal and lipid
raft  trafﬁcking through FLVHRY motif, and may promote
lysosome-dependent degradation of APP [44]. They found
that  lack of the FLVHRY motif reduces APP lysosomaland Ultrastructure 2 (2014) 57–66
targeting and increases APP distribution in lipid rafts in
cotransfected HEK293 cells, and in sortilin knockout mice
[44].  Other, membrane-integral or -peripheral associated
modulators of A42 peptide generation such as TSPAN 12
further  contributes to the kinetics of formation, cleavage,
processing, and speciation of APP [47]. Recently, the
participation of a membrane-spanning triggering receptor
expressed in myeloid cells 2 protein supports a role for yet
another  plasma membrane-integral glycoprotein in phago-
cytosis  and the clearance of A42 peptides before they
aggregate into SP [48]. Hence, depending on the processing
pathways and biological signals utilized, the plasma mem-
brane  can be the source of both beneﬁcial and detrimental
signals to further modulate amyloidogenic, inﬂammatory
or neurotrophic aspects of the AD process [5].
4. Genetic studies/bioinformatics analysis
The bioinformatics analysis revealed 3 important pro-
teins  “PS-1, PS-2, and APP” out of 74 proteins to be the key
pathological proteins in the evolution of AD [11].
4.1. Familial Alzheimer’s disease (FAD)
Missense mutations in the genes of APP, PS-1, and PS-2
that  are located on chromosomes 21, 14, and 1, respec-
tively share the common feature of altering the -secretase
cleavage of APP to increase the production of the amyloido-
genic A42, the primary component of amyloid plaques in
both  familial and sporadic AD [11,49]. The mutated com-
pounds, apart from increasing the ratio of A42 to A40,
may  down-regulate the calcium buffering activity of the
ER.  Decrease in the ER calcium pool would cause com-
pensatory increases in other calcium pools, particularly in
mitochondria with the consequent of enhanced formation
of  superoxide radical formation, and damage to the neu-
rons  and their senility [49].
Intriguingly, glucosylceramide (GlcCer) synthase
expression, an enzyme needed for the production of
GlcCer, is reduced in mutant PS1-transfected neuronal
cells without any effect on its mRNA expression [50].
Correspondingly, the amount of GlcCer and neuropro-
tective gangliosides which is synthesized from GlcCer, is
signiﬁcantly reduced in these cells. This reduction may
affect  the functions of lipid rafts and therefore make these
cells  vulnerable to cellular stress. In the same mutant
cells, the high afﬁnity nerve growth factor receptor “Trk”
which  is resident in lipid rafts, became also insensitive to
its  ligand, NGF. So, these cells became more sensitive to
oxidative stress than those of their parental cells [51].
5.  Lipids and Alzheimer’s disease connection
5.1. Phospholipids
Phospholipid alterations could lead to membrane insta-
bility  and synaptic loss, in that way, contribute to AD
pathology [52]. Plasma membrane-derived phospholipids
and esteriﬁed dococahexaenoicacid (DHA) are the sub-
strate  for phospholipases, and hence the precursors for
arachidonic acid cycle metabolites and cyclooxygenase
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onversion, that supports inﬂammatory signaling in the
NS  [53]. Plasma membranes can also provide free DHA
or  conversion via a 15-lipoxygenase into neuroprotectin
1, a potent neurotrophic docosanoid [54].
The availability of APP to - or -secretase determines
ow much of the pathogenic A peptides will be produced.
ince these two secretases/pathways are likely to be spa-
ially  separated within the cell, it is possible that alterations
f  APP trafﬁcking, caused by lipid changes, may  be the
rimary cause of the disease process [55]. Under normal
onditions, only a small portion of -secretase is local-
zed in lipid rafts. Targeting of -secretase to lipid rafts by
dding  an GPI anchor at the place of transmembrane and
-terminal domain increased the production of A. In con-
rast,  -secretase is under normal conditions exclusively
resent in non-raft fractions. Replacing its transmembrane
nd cytosolic domain with GPI anchor caused retarget-
ng it to lipid rafts and hence reduced amyloidogenic APP
rocessing. Overall, these results imply that regulation of
ipid  rafts protein targeting could be a good approach for
ontrolling APP amyloidogenic processing [56].
However, another signal for -secretase targeting
o lipid rafts is S-palmitoylation of Cys 474, 478,
82 and 485. Mutations of these Cys residues to Ala
elocated -secretase out of lipid rafts, but without
ffecting APP amyloidogenic processing [57]. Meanwhile,
-palmitoylation of -secretase complex subunits nicastrin
nd  aph-1 is important for their stability and raft localiza-
ion,  but not for -secretase processing of APP [58].
Another interesting approach was the synthesis of
he  membrane-anchored version of -secretase inhibitor,
hich was targeted to endosomes and lipid rafts, where
ts  local concentration was increased. In that way, this
nhibitor was more potent and focused on active -
ecretase [59].
.2.  Gangliosides (GM)
The  link of GM with AD pathology has been mostly
elated to their localization in lipid rafts which act as a
latform for GM1-induced aggregation of A peptide [60].
he  N-terminal region of A interacts with GM1  clusters
hrough hydrogen bonding and electrostatic interactions,
nd cholesterol may  facilitate GM1  clustering [59]. Extrac-
ion  of cortical lipid rafts from human AD brains showed
n  increase in both GM1  and GM2  despite an overall reduc-
ion  of GM [60], indicating that they accumulate in SP and
ay  be involved in the conversion of A to a neurotoxic
ligomeric form [14].
.3.  Cholesterol
Cholesterol has long been clinically associated with AD
athogenesis and this connection attracted many research
roups to explore the underlying causal role of cholesterol
n  APP processing for therapeutic intervention [60].
The  role of cholesterol has been especially clariﬁed by
he  ﬁndings of genetic, epidemiological, and biochem-
cal studies [36]. Several genes involved in cholesterol
etabolism or transport are AD susceptibility genes,
ncluding apolipoprotein E (ApoE), ApoJ, ATP-bindingand Ultrastructure 2 (2014) 57–66 61
cassette subfamily member 7 and sortilin-related receptor
[36].  Cholesterol dyshomeostasis has a close association
with the progression of Alzheimer’s cognitive impairment
[37], the synaptic loss [20], A [37], and NFTs pathology
[22,39,61]. Individuals with elevated cholesterol levels
during mid-life tend to develop AD pathology. The levels of
total  cholesterol and LDL in serum correlate with A load
in  the AD brains [62]. If cholesterol increases do elevate
lipid raft abundance, then it would increase A formation
and, on the contrary, low cholesterol levels will lead to
up-regulation of the activity of the -secretase [14,62].
However, quantiﬁcation of global cholesterol levels are
not  necessarily reﬂective of the number or distribution of
lipid  rafts [63]. Formation of the A “seed” and initiation of
A  aggregation was  shown to be cholesterol dependent.
It facilitated the insertion of A into the plasma mem-
brane. In so doing, A then destroys the cells’ membrane
integrity [64]. A peptides also modulate the metabolism
of cholesterol, in particular its esteriﬁcation rate, alter vesi-
cle  trafﬁcking and cholesterol homeostasis and prevent its
interaction  with low-density lipoprotein. It might also act
as  a component of lipoprotein complexes affecting reverse
cholesterol transport from neuronal tissue to the periphery
[65].
However, APP intracellular domain (AICD) was found
to  regulate cholesterol levels via lipoprotein receptor
apoE/LRP1. There are data reporting that cholesterol in
physiological concentrations can protect neuronal cells
against  A-induced toxicity and slow down the process
of  formation of toxic aggregates of A with metal ions, in
particular with aluminum [14,66]. Cholesterol depletion
disrupts lipid rafts with GPI-anchored PrPC being redis-
tributed into non-raft regions of the membrane. However,
depletion was  also shown to affect formation of function-
ally  active AICD resulting in reduced levels of expression of
the  amyloid-degrading enzyme, neprilysin [67].
5.4. Statins
In  retrospective studies patients treated with statin,
the inhibitor of hydroxymethyl glutaryl coenzyme A (HMG
CoA)  reductase, and the key enzyme in the biosynthesis of
cholesterol, showed signiﬁcantly reduced prevalence and
incidence  of AD. Statin may  reinforce -secretase activ-
ity  via modifying the biophysical properties of plasma
membranes or modulating the function of unidentiﬁed
protein kinases via the Rho/ROCK1 protein phosphoryla-
tion pathway [68] thus impeding A generation. It limits
the  amyloidogenic pathway via inhibiting the dimeriza-
tion of  secretase (the active form) and indirectly inhibits
-secretase activity [69]. It has also a role in limiting the
hyperphosphorylation of tau [68]. Sabbagh et al. [70] indi-
cated  that AD carriers of the KIF6 719Arg allele (Arg/Arg
homozygotes and Arg/Trp heterozygotes) is associated
with the effects of statin on cholesterol levels. In par-
ticular, ﬂuvastatin modiﬁes the trafﬁcking of APP and
increase lysosomal degradation of APP and hence facili-
tates  A clearance [71–73]. Atorvastatin prevents cognitive
impairments via improving hippocampal synaptic func-
tion,  and restores BBB integrity to enhance the clearance of
A  by anti-inﬂammatory lipid-modulating process [71,72].
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Statin has also non-lipid neuroprotective role, it attenuates
A  pathology via anti-inﬂammation, anti-atherosclerotic,
anti-oxidant, and anti-apoptotic actions [73]. It signiﬁ-
cantly suppressed the A-induced expression of IL-1,
inducible nitric oxide synthase by microglia and mono-
cytes, and rac1-dependent activation of NADPH oxidase
and  superoxide production [68]. As ApoE has been found
necessary for A pathology suppressing ApoE secretion by
statin  could inhibit the production of A and the formation
of  amyloid plaques [68,74].
Recently, however, the beneﬁts of statin with respect to
the  incidence or cognitive decline in patients with AD have
been  challenged. Some studies evidence beneﬁcial effects,
but  others show a slight or no clinically demonstrable
cognitive beneﬁt [68,72–74]. Statin can induce intracellu-
lar accumulation of APP, -secretase-cleaved fragments,
and A via an isoprenoid-dependent mechanism. Sim-
vastatin showed reduced A in treated patients, but no
corresponding improvement in cognitive performance. The
Cochrane  Dementia and Cognitive Improvement Group
study  reported that statin treatment had no effect on the
prevention or treatment of dementia [74]. However, taking
into  account the highly variable relationship between the
initiation  of statin therapy and the time and severity of the
AD,  it is very difﬁcult to get a conclusive assessment, so any
epidemiological meta-analysis study should use a deﬁned
set  of criteria for their patients [75].
Since all enzymes involved in APP processing are trans-
membrane proteins, as well as APP, it is logical to assume
that  lipid rafts could be involved in AD pathogenesis.
6. Factors inﬂuencing the initiation and
progression of AD
Among  the factors that inﬂuences the initiation and pro-
gression  and thus, have a role in the pathophysiology of
AD  are A42/A40 ratio and oligomers of these peptides;
oxidative stress; proinﬂammatory cytokines produced by
activated  glial cells, alterations in cholesterol homeostasis,
and alterations in cholinergic nervous system [11].
6.1.  Lipid raft redox signaling
Lipid  rafts microdomains, are able to form different
membrane macrodomains or platforms upon stimulations,
including redox signaling platforms, which serve as a crit-
ical  signaling mechanism to mediate or regulate cellular
activities or functions. In particular, assembling of NADPH
oxidase subunits and the recruitment of other related
receptors, effectors, and regulatory components, resulting,
in  turn, in the activation of NADPH oxidase and down-
stream redox regulation of cell functions [76].
6.2. Oxidative stress and neuronal death
Increased levels of reactive oxygen species (ROS), one
of  the major age-related damaging agents, produced by
normal  mitochondrial activity, inﬂammation and excess
glutamate levels, are proposed to accelerate neurode-
generative processes characteristic of AD [77]. A causes
hydrogen peroxide accumulation in cultured hippocampaland Ultrastructure 2 (2014) 57–66
neurons that results in oxidative damage to cellular
phospholipid membranes suggesting a role for lipid per-
oxidation in the pathogenesis of AD. The loss of membrane
integrity due to A-induced free-radical damage leads
to  cellular dysfunctions, such as inhibition of ion-motive
ATPase, loss of calcium homeostasis, inhibition of glial cell
Na+-dependent glutamate uptake system that results in
NMDA  receptors mediated delayed neurodegeneration,
loss of protein transporter function, disruption of signaling
pathways, and activation of nuclear transcription factors
and  apoptotic pathways [11].
6.3. Inﬂammation and neuronal death
Signiﬁcant dose-dependent increase in the produc-
tion of prointerleukin-1 (IL-1), IL-6, tumor necrosis
factor- (TNF-), monocyte chemoattractant protein-
1, macrophage inﬂammatory peptide-1, IL-8, mitogen-
activated protein kinase pathways, and macrophage
colony-stimulating factor were observed after exposure
to  preaggregated A42 as foreign material, since A
assemblies are apparently never observed during the
development of brain and in the immature nervous sys-
tem  [11]. The involvement of inﬂammatory process in the
pathogenesis of AD disease is further supported by the
observation that inhibition or neutralizing the actions of
TNF-  could be of beneﬁt to these patients [11,78].
6.4. Cholinergic system and AD
A primary clinical symptom of Alzheimer’s dementia
is the progressive deterioration in learning and mem-
ory  ability. There is a profound loss in the cholinergic
system of brain, including dramatic loss of choline acetyl-
transferase level, choline uptake, and acetylcholine (ACh)
level  in the neocortex and hippocampus and reduced
number of the cholinergic neurons in basal forebrain
and nucleus basalis of Meynert occurs that are closely
associated with cognitive deﬁcits in AD. Pharmacological
interventions that enhance or block further fall in ACh lev-
els  and thus, improve cholinergic neurotransmission are
known  to produce improvement in learning and memory
in  AD [11,79]. A could enhance free radical generation
and induce inﬂammation that could result in profound loss
in  the cholinergic system of brain [11]. ACh also has anti-
inﬂammatory actions, and hence, a decrease in its level may
further  aggravate the inﬂammatory process and progres-
sion  of AD. This “cholinergic anti-inﬂammatory pathway”
acts  by inhibiting the production of early proinﬂammatory
cytokines “TNF-, IL-1”, late proinﬂammatory mediators
“macrophage migration-inhibitory factor, and high mobil-
ity  group box 1 protein” and suppresses the activation of
NF-kB  expression. Even more, systemic injection of IL-1
decreased extracellular ACh in the hippocampus. In addi-
tion,  receptors of IL-1 are on APP mRNA positive cells and
its  ability to promote APP gene expression suggests that
IL-1  plays an important role in AD [80].Lipid raft localization has recently been linked to acetyl-
cholinesterase (AChE), although the functional implica-
tions of this are as yet unclear [81]. AChE inhibition by com-
pounds  such as rivastigmine or galantamine represents the
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ajor therapeutic option for treating the cognitive impair-
ent  seen in the early stages of AD. AChE exists in a number
f  different molecular forms (G1, G2, G4) of which the
etrameric G4 form is predominant in brain. In AD, brain
4  AChE levels fall as the disease progresses, while G1 and
2  levels rise somewhat, as compared to normal brains.
n  some brain regions with AD pathology, virtually all of
he  AChE is localized in these complexes, leading to the
uggestion that AChE may  promote A aggregation [82].
A  direct interaction between A and AChE has been pro-
osed, with binding occurring at the peripheral anionic
ite  (PAS) of the enzyme. Those AChE inhibitors which
ccupy the PAS (e.g., propidium) show the most signiﬁcant
eductions in ﬁbril formation since the catalytic site is not
equired  for interaction with A. Furthermore, monoclonal
ntibodies directed against the PAS inhibit ﬁbril formation,
hich has led to the development of PAS blockers, such as
he  DUO compounds, that also occupy the active site. They
how  inhibitory activity on AChE as well as inhibition of
40  ﬁbril formation and have been suggested as potential
ovel AD therapeutics targeting two facets of the disease
83].
AChE  is not a transmembrane protein, rather it is
nchored to the plasma membrane by the proline rich
embrane anchor (PriMA) which is a type I trans-
embrane protein and can be acylated. PriMA contains
holesterol recognition amino acid consensus motif which
equesters PriMA into lipid rafts and hence AChE is also
artly  associated with rafts [83].
.5. Exosomes and microRNAs
Plasma  membrane-derived exosomes are 30–90 nm
iameter vesicles secreted into the extracellular milieu
84].  Besides containing various proteins and molecular
onstituents reﬂective of their cells of origin, these vesi-
les  contain microRNAs as their most abundant nucleic
cids [85]. These organelles may  be capable of the paracrine
ransfer of genetic information between cells, either within
he  local environment of the brain or throughout the
ntire cerebrospinal or systemic circulation, at least in
art  dependent on plasma membrane-mediated biological
echanisms [84,85].
.6.  Dietary and environmental factors
Environmental and dietary factors which modulate
lasma membrane integrity, ﬂexibility and lipid raft effects
ight  not only be relevant in amyloidogenesis but also
n  paracrine microRNA trafﬁcking and the intercellular
preading of these soluble and mobile genetic signals.
or example, plasma membrane biophysics, dynamics,
nd lipid raft domain perturbation by cholesterol and
tatin  might not only have effects on cholesterol incor-
oration into membranes and lipid raft formation but
lso  on the exocytosis of exosomes [16,17,84]. Further-
ore, cholesterol can perturb the biophysical structure
f  the membrane and reorganize lipid raft domains, via
rotein–lipid and protein–protein interactions, contribut-
ng to membrane-mediated dysfunction of homeostatic
PP neurobiology [5,16]. Also, the potential involvementand Ultrastructure 2 (2014) 57–66 63
of  neurotropic viral infection with AD, involving processes
that  are plasma membrane-mediated, pro-inﬂammatory,
and evasive of the brain’s innate immune response [55,85].
7.  AD-type 2 diabetes (T2DM) co-morbidity
Substantial epidemiological evidence shows an
increased risk for developing AD in people with T2DM.
Yet  the underlying molecular mechanisms still remain
to  be elucidated. AD patients exhibit cerebral glucose
hypometabolism possibly due to impairments of insulin
signaling, brain insulin resistance and altered thiamine
metabolism. Moreover, AD brains show decreased insulin
levels,  decreased activity of insulin receptors and signs
of  compensatory mechanisms such as increased insulin
receptor density indicating AD as “type 3 diabetes”
[86]. Thence, the contribution of glucose transportation
abnormality and intracellular glucose catabolism dysfunc-
tion,  with the consequent multiple pathogenic cascades
induced by impaired cerebral glucose metabolism could
result  in neuronal degeneration and cognitive deﬁcits
in  AD patients [87]. Moreover, the induction of multiple
pathogenic factors as the result of glucose metabolism
abnormality such as oxidative stress, inﬂammation, mito-
chondrial dysfunction, advanced glycation end products
(AGEs), APOE 4, cholesterol and so forth appear to be an
important mediators that are likely to act synergistically in
promoting  AD pathology in diabetic subjects [87]. T2DM is
also  a risk factor for micro- as well as macro-vascular com-
plications. Vascular abnormalities are strongly associated
with AD [88] implying further involvement of T2DM in
disease  onset. Ischemic CVD caused by T2DM is positively
associated with AD through the shared pathological
mechanisms such as hyperinsulinemia, impaired insulin
signaling, oxidative stress, inﬂammatory mechanisms and
AGEs.  In vitro insulin-stimulated Akt phosphorylation
is decreased in hyperinsulinemic conditions in cortical
neurons [89]. All forms of A (monomers, oligomers
and A-derived diffusible ligands) can inhibit insulin
signaling by directly binding to the insulin receptor and
inhibit  insulin signal [88]. Even more, aging increases the
co-incidence of AD and T2DM. Tau phosphorylation at
AD-related epitopes, including Thr212, Thr231, Ser262,
and  Ser396, increased with age in the soluble brain
extracts of chronic T2DM obese rats and were accompa-
nied by synaptic protein loss. There was  also a marked
age-dependent accumulation of polyubiquitinated tau
in  neurons of these diabetic rats. In addition, the mRNA
and  protein levels of p62, a known cargo molecule that
transports polyubiquitinated tau to proteasomal and
autophagic degradation systems, decreased robustly with
age  in rats. The impaired degradation of polyubiquitinated
p-tau, due to age-T2DM-dependent and decreases in
p62  transcription is a primary mechanism underlying
increased AD-like pathology in a T2DM rat model as age
increases [90].
These  ﬁnding can guide to some potential possibilities
to uncover diagnostic biomarkers for AD from abnormal
glucose metabolism and to develop drugs targeting at
repairing insulin signaling impairment and correcting thi-
amine  metabolism abnormality [87–89].
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8. AD diagnosis
Certain diagnosis of AD can be made only post-mortem.
However, today in specialized clinics, using a combination
of  tools that include taking a disease history from patients
and  their families, and assessing cognitive function by neu-
ropsychological tests, in combination with neuroimaging
(CT, MRI  and PET) to exclude other causes of dementia
[91], AD can be diagnosed with more than 95% accuracy.
Neurological tests, which are still the gold standard for the
diagnosis  of AD, are mostly accurate in identifying indi-
viduals with already developed dementia. Structural MRI
provides  measures of brain atrophy, which reﬂect loss of
dendrites,  synapses and neurons [56].
CSF is the most informative ﬂuid source for neurodegen-
erative disease diagnosis/research, because of its constant
physical contact with brain. CSF biomarkers p-tau, total
tau  and A42 are useful for AD diagnosis and for iden-
tifying individuals with prodromal AD in mild cognitive
impairment (MCI) cases [91]. Low CSF levels of A strongly
correlate with intracranial amyloid plaques and high con-
centrations of CSF p-tau correlate with tau-associated NFTs
[91].  In humans, structural MRI  and CSF biomarkers allow
for  the indirect assessment of the cellular changes under-
lying  AD in vivo. The biggest challenge for clinicians and
for  application of novel therapies against AD is to accu-
rately recognize prodromal AD patients and/or individuals
with MCI  who  will develop AD. The multicenter study
found that these CSF biomarkers identify incipient AD
with  good accuracy, but with less accuracy compared
to single-center studies. Additional effort is needed for
standardization of analytical techniques and clinical pro-
cedures  to avoid variability between different centers
[56].
8.1. Lipids as biomarkers for AD diagnosis
Unchanged phosphatidylcholine (PC) levels, but
decreased lysoPC/PC ratio with elevation in different PC
metabolites, have been reported in the CSF from indi-
viduals with AD compared to individuals with memory
complaints, but without dementia, suggesting that AD is
accompanied with increased PC hydrolysis. Sphingolipid
alterations found in AD brain were also observed in the
CSF.  Increased levels of ceramides have been found in the
CSF  from individuals with AD compared to age-matched
individuals. Han and coworkers found approximately 40%
reduction  of sulfatides in the CSF in an early stage of AD and
unchanged levels of phosphatidylinositol (PI). The authors
suggested that CSF sulfatide/PI ratio could be a sensi-
tive and speciﬁc biomarker for early AD diagnosis [92].
Recently, Kosicek et al. [93] developed a high-performance
liquid chromatography–electrospray/mass spectrometry
method for CSF phospholipid screening for AD patients at
different  stages of the disease, including prodromal AD.
They  observed a statistically signiﬁcant increase (around
50%)  in sphingomyelin (SM) levels between prodromal
AD group and cognitively normal group, while PI, phos-
phatidylethanolamine (PE) and PC levels were unchanged
in  all examined groups [56,93].and Ultrastructure 2 (2014) 57–66
Recent work suggested that CSF levels of heart fatty
acid binding protein (HFABP), a lipid binding protein
involved with fatty acid metabolism and lipid transport
may  have diagnostic and prognostic value in the earliest
stages of AD [94]. Desikan et al. [95] suggested that CSF
HFABP reﬂects intra-cranial lipid biology and associates
with A-associated neurodegeneration irrespective of p-
tau.  Clinically, these ﬁndings suggested that HFABP may
represent an important modiﬁer of progression from amy-
loid  deposition to neurodegeneration [95]. In addition to
p-tau,  the HFABP/A/neurodegeneration axis may repre-
sent  an important area for further investigation [96].
Although CSF is the most informative sample for moni-
toring brain pathological processes, blood/plasma is much
easier  and less invasive to collect and, thus, is more suit-
able  for routine diagnosis and/or monitoring. Due to BBB
and  huge inﬂuence of diet and other body processes outside
the  brain on blood lipid levels, it is difﬁcult to make a direct
link  between blood phospholipid levels and neurodegener-
ative processes [56]. Mielke et al. [97] found signiﬁcantly
lower ceramide levels in plasma from individuals with MCI,
while  no difference was  observed in plasma ceramide lev-
els  between AD and non-demented controls.
Although so far reported CSF/blood phospholipid
changes are not speciﬁc and sensitive enough to be a diag-
nostic  biomarker, a combination of different sphingolipid
CSF and/or blood levels could potentially contribute to
more  precise AD diagnosis in a very early stage. However,
further research is required in order to clearly state that
any  of those lipids could be used as a biomarker [56].
9.  Conclusion
AD is an age-related devastating neurodegenerative dis-
order,  which severely impacts on the global economic
development and healthcare system. Though AD has been
studied  for more than 100 years since 1906, the exact
cause(s) and pathogenic mechanism(s) remain to be clar-
iﬁed.  Also, the efﬁcient disease-modifying treatment and
ideal  diagnostic method for AD are unavailable. A com-
bination of diet, lifestyle, vascular, genetic, and amyloid
related factors, enhance each other’s contribution in the
onset  and course of AD, will be more likely the cause
of the disease instead of one sole mechanism. To clarify
the  causes, pathogeneses and consequences on cerebral
hypometabolism in AD will help break the bottleneck of
current  AD study in ﬁnding ideal diagnostic biomarker
and disease-modifying therapy. Although the role of lipids
rafts  in AD pathogenesis is still controversial (as lipid
rafts are controversial per se), it is evident that spe-
ciﬁc membrane platforms are involved in APP, - and
-secretase co-localization, APP processing and formation
of  the pathogenic A peptide. Phospholipids provide an
optimal  membrane environment for protein interactions,
trafﬁcking and function. In terms of future progress, lipid
raft  research might open new avenues in regulation of
the  proteolytic and signaling processes involved in AD
pathology. However, any therapeutics aimed at manip-
ulation of lipid raft composition should be treated with
caution.
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